A double-blind, placebo-controlled study enrolled patients who had extended histories of receiving and tolerating BOTOX injections, with prior individualized adjustment of dose. The mean BOTOX dose administered to patients in this study was 236 Units (25th to 75th percentile range of 198 Units to 300 Units). The BOTOX dose was divided among the affected muscles [see Clinical Studies (14.7)]. Dosing in initial and sequential treatment sessions should be tailored to the individual patient based on the patient’s head and neck position, localization of pain, muscle hypertrophy, patient response, and adverse event history. The initial dose for a patient without prior use of BOTOX should be at a lower dose, with subsequent dosing adjusted based on individual response.
Masseter Botox is a procedure where Botox is injected directly into your masseter muscle – this is one of the muscles located on the side of your face that helps you chew. The masseter Botox procedure has become popular recently because it can slim a square face and reshape the jaw line.
In 1997, the original formulation was changed to reduce the protein load per dose, and since then treatment failure rates have dropped; however, experts estimate that 0.3 to seis% of people are still at risk of antibody development. The risk is greatest when dosages of more than 200 units per session are used, and reinjection occurs within one month. Experts are unsure if neutralizing antibodies resolve over time or if injections of botulinum toxin type B products are liftera useful in patients with neutralizing antibodies to type A.
Medicines that interact with Botox may either decrease its effect, affect how long it works, increase side effects, or have less of an effect when taken with Botox. An interaction between two medications does not always mean that you must stop taking one of the medications; however, sometimes it does.
Botox wears off with time as new nerve endings sprout and gradually reconnect with muscles or sweat glands, allowing them to work normally again in the treated area.
RADIESSE® and RADIESSE® (+) Injectable Implants are FDA-approved for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. RADIESSE® is also indicated for hand augmentation to correct volume loss in the dorsum of the hands.
The goal of cosmetic Botox is typically to soften wrinkles and achieve a refreshed, conterraneo look, not to eliminate all movement. Botox is also available to treat certain medical conditions.
Injection without surgical exposure or electromyographic guidance should not be attempted. Physicians should be familiar with electromyographic technique.
Botox Cosmetic is used for aesthetic purposes to smooth wrinkles and improve the appearance of platysma bands.
Botox is not approved for the prevention of of episodic migraine (14 headache days or fewer per month), and also should not be used to treat a common tension headache.
treat overactive bladder symptoms, such as urinary urgency, frequency, or incontinence, in adults when anticholinergics do not work well enough or cannot be taken
Because Botox contains albumin, a derivative of human blood there is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) and other viral diseases, but pelo cases of transmission have ever been identified.
Urinary retention: Post-void residual urine volume should be monitored in patients treated for OAB or adult detrusor overactivity associated with a neurologic condition who do not catheterize routinely, particularly patients with multiple sclerosis or diabetes mellitus. (5.13)
Clinical improvement generally begins within the first two weeks after injection with maximum clinical benefit at approximately six weeks post-injection. In the double-blind, placebo-controlled study most subjects were observed to have returned to pre-treatment status by 3 months post-treatment.